IPHYF
Innate Pharma S.A. OTC$1.50
Mkt Cap $140.7M
52w Low $1.31
11.9% of range
52w High $2.90
50d MA $2.15
200d MA $1.89
P/E (TTM)
-2.7x
EV/EBITDA
-3.6x
P/B
—
Debt/Equity
-1.0x
ROE
-658.9%
P/FCF
-3.1x
RSI (14)
—
ATR (14)
—
Beta
0.74
50d MA
$2.15
200d MA
$1.89
Avg Volume
35
About
Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical tr…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 17, 2025 | AMC | -0.33 | -0.29 | +12.4% | 2.00 | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | — |
| May 12, 2025 | AMC | -0.26 | -0.32 | -19.6% | 1.45 | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | — |
| Nov 13, 2024 | AMC | -0.30 | -0.33 | -9.8% | 1.28 | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | — |
| May 14, 2024 | AMC | -0.45 | -0.13 | +71.5% | — | — | — | — | — | — | — | — |
| Sep 14, 2023 | AMC | 0.09 | 0.02 | -74.4% | 3.00 | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | — |
| Mar 23, 2023 | AMC | -0.42 | -0.87 | -107.3% | 3.08 | -12.0% | -12.0% | -12.0% | -12.0% | -12.0% | -12.0% | — |
| Nov 14, 2022 | AMC | 0.39 | 0.08 | -79.2% | 2.08 | +10.6% | +10.1% | +10.1% | +10.1% | +10.1% | +10.1% | — |
| May 10, 2022 | AMC | -0.19 | -0.41 | -121.1% | 2.77 | +2.5% | +2.5% | +2.5% | +2.2% | +2.2% | +2.2% | — |
| Oct 26, 2021 | AMC | -0.30 | -0.36 | -17.8% | 5.59 | +0.0% | +0.0% | +0.0% | +1.3% | +1.3% | +1.3% | — |
| May 11, 2021 | AMC | -0.09 | -0.83 | -828.8% | 4.11 | +0.0% | +0.0% | -7.5% | -7.5% | -7.5% | -7.5% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Jun 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.34 | $3.34 | +0.0% | +0.0% | +0.0% | +0.0% | +0.6% | +0.6% |
| Nov 14 | SVB Leerink | Maintains | Outperform → Outperform | — | $2.08 | $2.08 | +0.0% | +0.0% | +10.1% | +10.1% | +10.1% | +10.1% |
| Sep 15 | Citigroup | Maintains | Buy → Buy | — | $2.60 | $2.60 | +0.0% | +0.0% | +0.0% | +0.0% | -0.8% | -1.2% |
| Aug 1 | SVB Leerink | Maintains | Outperform → Outperform | — | $3.16 | $2.69 | -14.9% | -11.4% | -11.4% | -11.4% | -12.0% | -12.0% |
| May 10 | SVB Leerink | Maintains | Outperform → Outperform | — | $2.77 | $2.77 | +0.0% | +0.0% | +2.5% | +2.5% | +2.2% | +2.2% |
| Sep 16 | SVB Leerink | Maintains | Outperform → Outperform | — | $5.68 | $5.75 | +1.2% | -0.9% | +38.7% | +33.8% | +26.6% | +26.6% |
| Sep 2 | SVB Leerink | Upgrade | Market Perform → Outperform | — | $3.66 | $4.01 | +9.6% | +7.9% | +94.0% | +51.9% | +54.4% | +74.0% |
| Sep 1 | SVB Leerink | Upgrade | Market Perform → Outperform | — | $3.55 | $3.66 | +3.1% | +3.1% | +11.3% | +100.0% | +56.6% | +59.2% |
| Mar 18 | SVB Leerink | Maintains | Market Perform → Market Perform | — | $4.75 | $4.50 | -5.3% | -1.7% | -1.7% | -1.7% | -1.7% | -1.7% |
Data updated apr 27, 2026 10:02pm
· Source: massive.com